Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic.

Skowronski DM, Leir S, De Serres G, Murti M, Dickinson JA, Winter AL, Olsha R, Croxen MA, Drews SJ, Charest H, Martineau C, Sabaiduc S, Bastien N, Li Y, Petric M, Jassem A, Krajden M, Gubbay JB.

Euro Surveill. 2019 Apr;24(15). doi: 10.2807/1560-7917.ES.2019.24.15.1900104.

2.

Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children < 2 years during seasonal influenza peaks.

Amini R, Gilca R, Boucher FD, Charest H, De Serres G.

Infection. 2019 Feb 23. doi: 10.1007/s15010-019-01287-5. [Epub ahead of print]

PMID:
30798473
3.

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.

Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Chan T, Bastien N, Li Y, Krajden M, De Serres G.

Euro Surveill. 2019 Jan;24(4). doi: 10.2807/1560-7917.ES.2019.24.4.1900055.

4.

Vaccine effectiveness against lineage matched and mismatched influenza B viruses across 8 seasons in Canada, 2010-11 to 2017-18.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Fonseca K, Charest H, Martineau C, Hickman R, Chan T, Jassem A, Petric M, Rose C, Bastien N, Li Y, Krajden M.

Clin Infect Dis. 2018 Oct 11. doi: 10.1093/cid/ciy876. [Epub ahead of print]

5.

Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?

Chambers C, Skowronski DM, Rose C, Serres G, Winter AL, Dickinson JA, Jassem A, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Petric M, Krajden M.

Open Forum Infect Dis. 2018 Sep 4;5(9):ofy211. doi: 10.1093/ofid/ofy211. eCollection 2018 Sep.

6.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M.

Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035. Erratum in: Euro Surveill. 2018 Jul;23(30):.

7.

HIV-1 envelope sequence-based diversity measures for identifying recent infections.

Kafando A, Fournier E, Serhir B, Martineau C, Doualla-Bell F, Sangaré MN, Sylla M, Chamberland A, El-Far M, Charest H, Tremblay CL.

PLoS One. 2017 Dec 28;12(12):e0189999. doi: 10.1371/journal.pone.0189999. eCollection 2017.

8.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

9.

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y.

J Infect Dis. 2017 Sep 15;216(6):697-702. doi: 10.1093/infdis/jix393.

10.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M.

Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

11.

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y, Smith DJ.

J Infect Dis. 2017 Apr 1;215(7):1059-1099. doi: 10.1093/infdis/jix074.

12.

Temporal Changes in Pediatric Gastroenteritis after Rotavirus Vaccination in Quebec.

Doll MK, Gagneur A, Tapiéro B, Charest H, Gonzales M, Buckeridge DL, Quach C.

Pediatr Infect Dis J. 2016 May;35(5):555-60. doi: 10.1097/INF.0000000000001077.

PMID:
26855410
13.

Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.

Doll MK, Buckeridge DL, Morrison KT, Gagneur A, Tapiero B, Charest H, Quach C.

Vaccine. 2015 Dec 16;33(51):7307-7314. doi: 10.1016/j.vaccine.2015.10.118. Epub 2015 Nov 3.

PMID:
26546262
14.

Predictors of hospitalization for lower respiratory tract infection in children aged <2 years in the province of Quebec, Canada.

Zhou Z, Gilca R, Deceuninck G, Boucher FD, Charest H, DE Wals P.

Epidemiol Infect. 2016 Apr;144(5):1035-44. doi: 10.1017/S0950268815002204. Epub 2015 Sep 18.

PMID:
26381086
15.

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.

Gilca R, Skowronski DM, Douville-Fradet M, Amini R, Boulianne N, Rouleau I, Martineau C, Charest H, De Serres G.

PLoS One. 2015 Jul 22;10(7):e0132195. doi: 10.1371/journal.pone.0132195. eCollection 2015.

16.

Draft Genome Sequences of Two Toxigenic Corynebacterium ulcerans Strains.

Domingo MC, Fournier E, Massé C, Charest H, Bernard K, Côté JC, Tremblay C.

Genome Announc. 2015 Jun 25;3(3). pii: e00699-15. doi: 10.1128/genomeA.00699-15.

17.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
18.

Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season.

Gilca R, Amini R, Douville-Fradet M, Charest H, Dubuque J, Boulianne N, Skowronski DM, De Serres G.

Open Forum Infect Dis. 2014 Sep 22;1(2):ofu086. doi: 10.1093/ofid/ofu086. eCollection 2014 Sep.

19.

Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, Drews SJ, Fonseca K, Charest H, Gubbay JB, Petric M, Krajden M, Kwindt TL, Martineau C, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2015 Jan 29;20(4). pii: 21022. No abstract available.

20.

A significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral load.

Charest H, Doualla-Bell F, Cantin R, Murphy DG, Lemieux L, Brenner B, Hardy I, Moisi D, Lo E, Baril JG, Wainberg MA, Roger M, Tremblay C.

PLoS One. 2014 Oct 8;9(10):e109420. doi: 10.1371/journal.pone.0109420. eCollection 2014.

21.

Genomic characterization of a large outbreak of Legionella pneumophila serogroup 1 strains in Quebec City, 2012.

Lévesque S, Plante PL, Mendis N, Cantin P, Marchand G, Charest H, Raymond F, Huot C, Goupil-Sormany I, Desbiens F, Faucher SP, Corbeil J, Tremblay C.

PLoS One. 2014 Aug 8;9(8):e103852. doi: 10.1371/journal.pone.0103852. eCollection 2014.

22.

Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y.

PLoS One. 2014 Mar 25;9(3):e92153. doi: 10.1371/journal.pone.0092153. eCollection 2014.

23.

Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014.

Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, Fonseca K, Gubbay J, Charest H, Petric M, Krajden M, Mahmud S, Van Caeseele P, Kwindt T, Eshaghi A, Bastien N, Li Y.

Euro Surveill. 2014 Feb 6;19(5). pii: 20690. Erratum in: Euro Surveill. 2014;19(6):20698.

24.

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.

Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, Dickinson JA, Fonseca K, Charest H, Bastien N, Li Y, Kwindt TL, Mahmud SM, Van Caeseele P, Krajden M, Petric M.

J Infect Dis. 2014 Jul 1;210(1):126-37. Epub 2014 Jan 19.

PMID:
24446529
25.

Detection of influenza H7N9 virus: all molecular tests are not equal.

Hatchette TF, Drews SJ, Bastien N, Li Y, German G, Antonishyn N, Charest H, Mazzulli T, Fonseca K, Krajden M, Petric M, Dust K, LeBlanc JJ.

J Clin Microbiol. 2013 Nov;51(11):3835-8. doi: 10.1128/JCM.01808-13. Epub 2013 Aug 21.

26.

Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013.

Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter AL, Mahmud SM, Sabaiduc S, Gubbay JB, Charest H, Petric M, Fonseca K, Van Caeseele P, Kwindt TL, Krajden M, Eshaghi A, Li Y.

Euro Surveill. 2013 Jan 31;18(5). pii: 20394.

27.

A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.

Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, Gubbay J, Fonseca K, Charest H, Crowcroft NS, Fradet MD, Bastien N, Li Y, Krajden M, Sabaiduc S, Petric M.

Clin Infect Dis. 2012 Aug;55(3):332-42. doi: 10.1093/cid/cis431. Epub 2012 Apr 26.

PMID:
22539661
28.

Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants.

Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, Winter AL, Hottes TS, Fonseca K, Charest H, Drews SJ, Sabaiduc S, Bastien N, Li Y, Gardy JL, Petric M.

J Infect Dis. 2012 Jun 15;205(12):1858-68. doi: 10.1093/infdis/jis283. Epub 2012 Apr 9.

PMID:
22492921
29.

Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec.

Brenner BG, Roger M, Stephens D, Moisi D, Hardy I, Weinberg J, Turgel R, Charest H, Koopman J, Wainberg MA; Montreal PHI Cohort Study Group.

J Infect Dis. 2011 Oct 1;204(7):1115-9. doi: 10.1093/infdis/jir468.

30.

Evidence of viremia in 2 cases of severe pandemic influenza A H1N1/09.

Oughton M, Dascal A, Laporta D, Charest H, Afilalo M, Miller M.

Diagn Microbiol Infect Dis. 2011 Jun;70(2):213-7. doi: 10.1016/j.diagmicrobio.2010.12.013. Epub 2011 Mar 11.

PMID:
21397429
31.

Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.

Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M.

J Med Virol. 2011 May;83(5):751-9. doi: 10.1002/jmv.22047. Epub 2011 Feb 25.

PMID:
21360548
32.

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.

Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, Gubbay JB, Bastien N, Li Y, Petric M.

BMJ. 2011 Feb 3;342:c7297. doi: 10.1136/bmj.c7297.

33.

Novel influenza A (H1N1): clinical features of pediatric hospitalizations in two successive waves.

Launay E, Ovetchkine P, Saint-Jean M, Coïc L, Ducruet T, Charest H, Desmarais N, Lamarre V, Tapiéro B.

Int J Infect Dis. 2011 Feb;15(2):e122-30. doi: 10.1016/j.ijid.2010.08.006. Epub 2010 Dec 8.

34.

Analytical performance of norovirus real-time RT-PCR detection protocols in Canadian laboratories.

Mattison K, Grudeski E, Auk B, Brassard J, Charest H, Dust K, Gubbay J, Hatchette TF, Houde A, Jean J, Jones T, Lee BE, Mamiya H, McDonald R, Mykytczuk O, Pang X, Petrich A, Plante D, Ritchie G, Wong J, Booth TF.

J Clin Virol. 2011 Feb;50(2):109-13. doi: 10.1016/j.jcv.2010.10.008. Epub 2010 Nov 10.

PMID:
21071266
35.

Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections.

Papenburg J, Baz M, Hamelin MÈ, Rhéaume C, Carbonneau J, Ouakki M, Rouleau I, Hardy I, Skowronski D, Roger M, Charest H, De Serres G, Boivin G.

Clin Infect Dis. 2010 Nov 1;51(9):1033-41. doi: 10.1086/656582.

PMID:
20887206
36.

Prevalence of West Nile virus in wild American Kestrels (Falco sparverius) of southern Quebec, Canada.

Dubé MC, Bird DM, Dibernardo A, Lindsay LR, Charest H.

J Wildl Dis. 2010 Apr;46(2):603-7.

PMID:
20688659
37.

Contagious period for pandemic (H1N1) 2009.

De Serres G, Rouleau I, Hamelin ME, Quach C, Skowronski D, Flamand L, Boulianne N, Li Y, Carbonneau J, Bourgault A, Couillard M, Charest H, Boivin G.

Emerg Infect Dis. 2010 May;16(5):783-8. doi: 10.3201/eid1605.091894.

38.

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada.

Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, Rosella LC, Dickinson JA, Gilca R, Sethi P, Ouhoummane N, Willison DJ, Rouleau I, Petric M, Fonseca K, Drews SJ, Rebbapragada A, Charest H, Hamelin ME, Boivin G, Gardy JL, Li Y, Kwindt TL, Patrick DM, Brunham RC; Canadian SAVOIR Team.

PLoS Med. 2010 Apr 6;7(4):e1000258. doi: 10.1371/journal.pmed.1000258.

39.

Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.

Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A.

Antimicrob Agents Chemother. 2010 Jun;54(6):2473-9. doi: 10.1128/AAC.00096-10. Epub 2010 Apr 5.

40.

Real-time molecular beacon NASBA for rapid and sensitive detection of norovirus GII in clinical samples.

Lamhoujeb S, Charest H, Fliss I, Ngazoa S, Jean J.

Can J Microbiol. 2009 Dec;55(12):1375-80. doi: 10.1139/W09-105.

PMID:
20029529
41.

Multicenter comparison of two norovirus ORF2-based genotyping protocols.

Mattison K, Grudeski E, Auk B, Charest H, Drews SJ, Fritzinger A, Gregoricus N, Hayward S, Houde A, Lee BE, Pang XL, Wong J, Booth TF, Vinjé J.

J Clin Microbiol. 2009 Dec;47(12):3927-32. doi: 10.1128/JCM.00497-09. Epub 2009 Oct 21.

42.

Field performance of a rapid diagnostic test for influenza in an ambulatory setting.

Rouleau I, Charest H, Douville-Fradet M, Skowronski DM, De Serres G.

J Clin Microbiol. 2009 Sep;47(9):2699-703. doi: 10.1128/JCM.00762-09. Epub 2009 Jul 8.

43.

Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.

Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, Kwindt TL, Chan T, Bastien N, Charest H, Li Y.

J Infect Dis. 2009 Jan 15;199(2):168-79. doi: 10.1086/595862.

PMID:
19086914
44.

Transmission networks of drug resistance acquired in primary/early stage HIV infection.

Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA; Montreal PHI Cohort and HIV Prevention Study Groups.

AIDS. 2008 Nov 30;22(18):2509-15. doi: 10.1097/QAD.0b013e3283121c90.

45.

Evaluation of a commercial direct fluorescent-antibody assay for human metapneumovirus in respiratory specimens.

Vinh DC, Newby D, Charest H, McDonald J.

J Clin Microbiol. 2008 May;46(5):1840-1. doi: 10.1128/JCM.01554-07. Epub 2008 Mar 26.

46.

Fatal zygomycosis caused by Mucor indicus in a child with an implantable left ventricular assist device.

de Repentigny L, St-Germain G, Charest H, Kokta V, Vobecky S.

Pediatr Infect Dis J. 2008 Apr;27(4):365-9. doi: 10.1097/INF.0b013e3181634f2b. Review.

PMID:
18316980
47.

Phylogenetic analysis of norovirus isolates involved in some Canadian gastroenteritis outbreaks in 2004 and 2005.

Lamhoujeb S, Charest H, Fliss I, Ngazoa S, Jean J.

Can J Microbiol. 2007 Oct;53(10):1133-40.

PMID:
18026205
48.

High rates of forward transmission events after acute/early HIV-1 infection.

Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R, Rouleau D, Bruneau J, Leblanc R, Legault M, Tremblay C, Charest H, Wainberg MA; Quebec Primary HIV Infection Study Group.

J Infect Dis. 2007 Apr 1;195(7):951-9. Epub 2007 Feb 16.

PMID:
17330784
49.

Epidemiological survey of human metapneumovirus infection in a large pediatric tertiary care center.

Chano F, Rousseau C, Laferrière C, Couillard M, Charest H.

J Clin Microbiol. 2005 Nov;43(11):5520-5.

50.

HIV-1 genetic diversity in antenatal cohort, Canada.

Akouamba BS, Viel J, Charest H, Merindol N, Samson J, Lapointe N, Brenner BG, Lalonde R, Harrigan PR, Boucher M, Soudeyns H.

Emerg Infect Dis. 2005 Aug;11(8):1230-4.

Supplemental Content

Loading ...
Support Center